Acurx Pharmaceuticals, Inc. — 2021 Form 10-K Summary
Business context and reporting period
For the fiscal year ended December 31, 2021, Acurx was a clinical-stage biopharmaceutical company with no approved products and no product revenue. Its lead candidate, ibezapolstat, is in development for Clostridioides difficile infection (CDI); its earlier-stage ACX-375C program targets other Gram-positive infections, including MRSA and VRE. Both programs use the company’s investigational DNA polymerase IIIC inhibitor approach.
Financial results and liquidity
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $2.03 million | $2.20 million |
| General and administrative expense | $10.78 million | $2.40 million |
| Total operating expenses | $12.81 million | $4.60 million |
| Net loss | $12.75 million | $4.60 million |
| Cash used in operating activities | $5.01 million | $3.35 million |
| Cash at year-end | $12.96 million | $3.18 million |
At December 31, 2021, total assets were $13.25 million, total liabilities were $0.84 million, and shareholders’ equity was $12.41 million. The filing reports no outstanding debt at year-end; the $66,503 Paycheck Protection Program loan was fully forgiven in April 2021. Margins are not meaningful because the company had no revenue.
Changes versus the prior year
- Net loss increased by $8.15 million, primarily because general and administrative expense rose $8.39 million. The company attributed the increase chiefly to share-based and executive compensation and higher legal, accounting and consulting costs.
- Research and development expense declined by about $0.17 million, as lower consulting costs more than offset increased manufacturing costs for the Phase 2b trial.
- Cash increased following the June 2021 IPO, which generated $14.80 million in net proceeds. Financing cash flow was $14.80 million in 2021, compared with $4.04 million from private placements and the PPP loan in 2020.
Outlook, milestones and material risks
- The Phase 2b, vancomycin-controlled study began enrolling on December 3, 2021. It is designed for 64 patients: 32 receiving ibezapolstat 450 mg twice daily and 32 receiving vancomycin 125 mg four times daily, each for 10 days. The company plans to discuss Phase 3 requirements with the FDA after Phase 2b; it cites a possible two-trial Phase 3 program, subject to regulatory discussions.
- In the earlier Phase 2a study, all 10 enrolled patients met reported clinical cure and sustained-cure endpoints, with no treatment-related serious adverse events reported. The trial stopped after 10 participants rather than the planned 20 on the recommendation of the Scientific Advisory Board. These small-study findings do not establish efficacy in larger trials.
- Management believes year-end cash can fund anticipated operations for at least 12 months from issuance of the financial statements. The company expects continuing losses and may need additional capital; it has no committed source of future financing. Equity financing could dilute shareholders, while partnerships could require rights concessions.
- Management’s market estimates are speculative, not company guidance: it estimated potential peak ibezapolstat sales of about $500 million and ACX-375C sales of about $1 billion if developed and approved. These estimates depend on clinical success, approval, pricing, reimbursement and market adoption.
- Key risks include clinical-trial failure or delay, regulatory uncertainty, patient enrollment and COVID-19 effects, reliance on contract manufacturers and vendors, limited personnel, competition, and the need for additional funding. As of March 2022, the company reported three full-time employees, none engaged in R&D.
- Disclosure controls were not effective at year-end due to a material weakness involving inadequate segregation of duties. Management had engaged an outside specialist and hired a controller expected to start in April 2022; remediation was not yet complete. The financial statement audit gave an unqualified opinion, but the auditor did not opine on internal-control effectiveness.
Most important facts for investors to verify
- Phase 2b enrollment, completion, endpoints and results, including the comparison with vancomycin and any subsequent FDA feedback on Phase 3 requirements.
- Cash runway against actual operating cash use, trial costs and any financing or partnership needs after year-end.
- Progress and effectiveness of remediation of the material weakness in financial reporting controls.
- Manufacturing supply continuity and dependence on key vendors, as well as the timing and cost of later-stage development.
- Basis and assumptions behind management’s market-size, pricing and peak-sales estimates; these are projections, not realized results.